 |
|
|
| |
Lipid Parameters and Lipid-Modifying Agent Use in
Participants Initiating F/TAF or F/TDF
for PrEP in the DISCOVER Trial
|
| |
| |
AIDS 2022, 29 July–2 August, Montreal, Quebec, Canada
Karam Mounzer,1 Amanda Clarke, Susanne Doblecki-Lewis, Cecile Tremblay, Gordon Crofoot, Ann Avery,6 Jason Szabo,7
Christoph C. Carter,8 Yongwu Shao,8 Ramin Ebrahimi,8 Moupali Das,8 Alex Kintu,8 Jenna Yager,8 Carlo Hojilla,8 Jared Baeten,8 David Wohl9
1Philadelphia FIGHT Community Health Centers, Philadelphia, Pennsylvania, USA; 2Royal Sussex County Hospital, and Brighton and Sussex Medical School, Brighton, UK; 3University of Miami Miller School of Medicine, Florida, USA; 4Centre Hospitalier de l’Universite de Montreal, Quebec, Canada; 5The Crofoot Research Center, Houston, Texas, USA; 6MetroHealth Medical Center, Cleveland, Ohio, USA; 7Research Institute of the McGill University Health Centre, Montreal; 8Gilead Sciences, Inc., Foster City, California, USA; 9University of North Carolina at Chapel Hill, USA
|
| |
|
|
|
|
|
